



Advancing Hepatitis C Elimination in Africa: Insights from Egypt

Izere Salomon ^{1,2}, Sibomana Olivier¹, Ndayambaje Egide ¹

¹Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda; ²YP-CDN Rwanda (Rwanda Young Professional Chronic Disease Network), Kigali Rwanda

Correspondence: Izere Salomon, Email izesajw73@gmail.com

Abstract: The hepatitis C virus (HCV) poses a significant risk to global public health and is linked to life-threatening clinical outcomes. According to the WHO, there are an estimated 58 million people worldwide who have a chronic hepatitis C virus (HCV) infection; there are 1.5 million new cases and more than 350,000 fatalities from HCV-related illnesses each year. Even though there are numerous diagnostic techniques, the lack of funding, inadequate healthcare infrastructure, and low public awareness of the Hepatitis C virus can make diagnosis and treatment difficult to obtain throughout the continent. The frequency of hepatitis C virus infection is highest in African nations (1–26%), raising serious concerns about the virus's impact on public health. The world's highest rate of Hepatitis C virus infection was found in Egypt, an African nation. Its nationwide hepatitis C elimination program stands out as a prime example of achievement, having screened, and treated over 60 million people, significantly reducing the disease's incidence and prevalence. Other African nations facing similar difficulties might benefit greatly from Egypt's methods, which provide valuable insights and flexible frameworks. This review aims to shed light on Egypt's successes and challenges while offering strategic recommendations to African nations to quicken their progress in eliminating hepatitis C.

Keywords: hepatitis C, elimination, Africa, Egypt, direct-acting antivirals, policy insights, hepatitis virus

Introduction

The Hepatitis C virus (HCV) is a type of tiny enveloped positive stranded RNA virus that is a member of the *Flaviviridae* family and genus *Hepacivirus*. The World Health Organization (WHO) estimates that over 350,000 people die each year from complications and diseases associated to hepatitis C, and that over 58 million people have a chronic hepatitis C virus (HCV) infection.¹ In contrast to other hepatitis viruses (like HAV, HDV, and HEV), HCV is more likely to cause chronic infections, which can go years without causing symptoms and result in long-term liver damage;^{1,2} it also demonstrates remarkable genetic diversity, with multiple genotypes and subtypes that influence how well a treatment works and how the disease progresses.; Additionally, unlike Hepatitis A and B, there is no known vaccine for HCV; instead, prevention is based on avoiding risk factors and engaging in safe behaviors. Furthermore, HCV sometimes progresses silently with minimal early signs that may occasionally even manifest concurrently with considerable liver damage.^{1–4} Chronic liver disease (CLD) is primarily caused by HCV, and cirrhosis, hepatocellular carcinoma, liver failure, and death have all been associated with long-term infection.^{5–7} When it comes to hepatitis viruses, intravenous drug use, risky medical operations, and blood transfusions are the most prevalent means of transmission. In contrast, other hepatitis viruses (such as HEV and HAV) mostly spread through contaminated water and food.^{8,9}

According to estimates available, the hepatitis C virus (HCV) continues to be a major public health concern in Africa, where over 91 million people have either hepatitis B or C, accounting for 26% of the global burden of these infections and causing approximately 125,000 deaths annually. Nevertheless, a number of obstacles stand in the way of effective management, as over 70% of hepatitis B cases worldwide occur in Africa, requiring intensive prevention and treatment initiatives.^{1,4,9,10} Traditional practices (including scarification), a family history of viral hepatitis, geographic location, unsafe transfusion practices, unsafe injection drug use, and risky sexual activities involving blood exposure are some of

the risk factors for HCV infection in Africa.^{11–13} Despite the availability of affordable, efficient Direct-Acting Antiviral (DAA) drugs that can cure HCV in most cases with little side effects,^{2,10,11} many obstacles prevent people from accessing healthcare, including exorbitant expenses, scarcity of resources, and low awareness. Numerous nations implemented HCV elimination initiatives and set a 2030 target of 90% lower chronic HCV incidence and 65% lower HCV mortality.¹⁴ However, the negative effects of the SARS-CoV-2 epidemic on the healthcare system caused HCV elimination programs to be delayed or stopped, as a result, there are still large gaps in viral hepatitis testing and treatment options.^{14–17}

However, among these difficulties are also some examples of creativity and achievement in the area that can act as templates for quickening the eradication of hepatitis C in other nations.¹⁸ Egypt had the greatest frequency of HCV in the world, with over 6 million cases stemming from improper injection methods during the country's large treatment operations to eradicate schistosomiasis in the 1960s. The fast spread of HCV was caused by non-disposable needle reuse and lack of sterilization.

Notably, Egypt's noteworthy advancements in the fight against hepatitis C offer hope. Egypt has received international attention for its efforts to eradicate hepatitis C, and its preemptive measures have drastically reduced the prevalence of new infections.¹⁹ Egypt has started a national drive to eradicate hepatitis C by 2023, dubbed “**100 million seha**” (100 million healthy lives), providing free testing and treatment to everybody. This initiative is the result of years of coordinated government action.^{19–22}

The purpose of this review is to highlight Egypt's progress and challenges in their effort to eradicate hepatitis C, providing other African nations that are dedicated to doing the same with insightful analysis and actionable suggestions.

Prevalence of Hepatitis C in Africa

In Africa, the hepatitis C virus (HCV) continues to be a serious public health concern. Although there is a significant HCV disease burden in Sub-Saharan Africa, there is no comprehensive epidemiology or understanding of the disease burden in this region. One major obstacle in this regard is the dearth of trustworthy prevalence statistics and population-based research. As stated by WHO With roughly 60 million having hepatitis B and 10 million having hepatitis C, over 70 million Africans suffer from chronic viral hepatitis. HCV infection is currently curable, however hepatitis B infection is not prevented or treated.²³ Around 125,000 people worldwide have died from hepatitis B and C, with 26% of cases occurring in the African continent. Furthermore, modeled data indicates that 600,000 people in South Africa are estimated to be infected with HCV, representing a prevalence of less than 1%. Over 71 million people worldwide suffer from HCV, with 14% of those affected living in sub-Saharan Africa.^{1,3,4,24} Some of the greatest HCV prevalence rates are seen in North Africa, most notably in Egypt, which formerly had one of the highest rates of HCV infection in the world with over 6 million infected, mostly as a result of improper injection practices et al^{4,24,25} The Democratic Republic of the Congo, Nigeria, Cameroon, Gabon, Libya, and others have notable prevalence rates. The fact that several studies in the same area may find different prevalence numbers is significant because it illustrates the difficulty of epidemiological surveillance. A sizable percentage of the HCV epidemic worldwide in 2019 was concentrated in the African continent, where the illness was also responsible for a sizable number of fatalities (Figure 1). The goal of the WHO's continuous efforts to monitor and manage this public health issue is to lessen the prevalence and effects of HCV throughout the continent.

Increasing the coverage of routine childhood immunization against Hepatitis B, which is now at 72% for the region—below the worldwide target of 90%—is one of the ways the WHO is fighting Hepatitis B and C. Additionally, the rates of Hepatitis C diagnosis and treatment remain shockingly low, with around 5% of infected individuals receiving treatment and only 5% receiving a diagnosis.^{3,27}

In order to lessen the prevalence of Hepatitis C in Africa, these data emphasize the critical need for enhanced healthcare measures, such as immunization, safe injection techniques, and access to diagnosis and treatment services.


Methods for Africans to Be Free of Hepatitis C

Even though there are little comprehensive and trustworthy HCV seroepidemiological data in many regions of sub-Saharan Africa, the estimations that are now available point to a significant burden.

Hepatitis C: total number of deaths, 2019

The estimated annual number of deaths from hepatitis C virus¹, including both acute and chronic disease².

Our World
in Data



Data source: IHME, Global Burden of Disease Study (2019)

[OurWorldInData.org/causes-of-death](https://ourworldindata.org/causes-of-death) | CC BY

1. Hepatitis virus: Hepatitis viruses are a group of viruses that cause inflammation of the liver. This results in symptoms like jaundice, fatigue, and liver dysfunction, and can range from a mild illness lasting a few weeks (acute hepatitis) to a severe, lifelong condition (chronic hepatitis) that can include cirrhosis. There are five main hepatitis viruses, which are called types A, B, C, D, and E. Each of these viruses can cause liver inflammation, but they vary in how they spread, their severity, and their geographical distribution. For example, Hepatitis A and E are primarily transmitted through contaminated food and water, while B, C, and D are mainly transmitted through blood and body fluids. Hepatitis B and C viruses are also known to increase the risks of liver cancer.

2. Acute vs chronic diseases: In a medical context, 'acute' refers to conditions that arise suddenly or last a short amount of time, while 'chronic' refers to conditions that develop gradually over a long period of time and tend to persist.

Figure 1 The Global Burden of Disease Study (2019) by IHME estimates the total number of deaths caused by the hepatitis C virus in 2019.

Note: Reproduced with permission from IHME, Global Burden of Disease Study. (2019). Available from: <https://ourworldindata.org/grapher/hepatitis-c-number-of-deaths?region=Africa>.²⁶

The resources required to eradicate viral hepatitis are currently at hand, but a global coordinated response to the disease is being implemented slowly and with several obstacles. Among these are low levels of overall health investment; insufficient data and weak surveillance systems; inadequate infrastructure; low awareness among primary care practitioners, at-risk populations, and policymakers; high costs of certain diagnostics and treatments; and a failure to prioritize viral hepatitis. When building models of national plans for management of HCV in the region, systematic population-based seroprevalence investigations should be incorporated to determine the true burden. Significantly, the lack of seroprevalence statistics should not impede the growth of HCV screening programs for the general public and at-risk individuals, nor should it impede the development of HCV infection identification, therapy linkage, and efficacious treatment.

Raising awareness, enhancing infrastructure, and implementing focused interventions are all necessary to combat this silent epidemic and lower the prevalence of HCV in the area. The World Health Organization's 2016 Global Health Sector Strategy on viral hepatitis established a target of 90% lower incidence and 65% lower mortality from 2015 levels

Table 1 Impact and Coverage Indicators, Targets, and Milestones for Viral Hepatitis by 2030

| | Indicator | Baseline- 2020 | Targets-2025 | Targets-2030 |
|------------|--|---|------------------------------------|---------------------------------|
| Impact | Prevalence of hepatitis B surface antigen (HBsAg) in children under five years of age | 0.94% | 0.5% | 0.1% |
| | Annual number of new cases of hepatitis B | 1.5 million fresh instances 20 out of 100,000 | 850 000 new cases 11 per 100 000 | 170 000 new cases 2 per 100 000 |
| | The annual number of new cases of hepatitis C infections | 1.575 million new cases 20 per 100 000 | 1 million new cases 13 per 100 000 | 350 000 new cases 5 per 100 000 |
| | Number of newly diagnosed cases of hepatitis C among drug injectors annually | 8 per 100 | 3 per 100 | 2 per 100 |
| | Annual number of deaths due to hepatitis B | 820 000 deaths 10 per 100 000 | 530 000 deaths 7 per 100 000 | 310 000 deaths 4 per 100 000 |
| | Number of hepatitis C fatalities annually | 290 000 deaths 5 per 100 000 | 240 000 deaths 3 per 100 000 | 140 000 deaths 2 per 100 000 |
| Coverage | Hepatitis B: proportion of patients diagnosed and treated for hepatitis B | 30%/30% | 60%/50% | 90%/80% |
| | Hepatitis C: The proportion of individuals with hepatitis C who have been diagnosed and treated | 30%/30% | 60%/50% | 90%/80% |
| | The proportion of infants who have benefited from receiving a hepatitis B vaccination dose on time for their birth as well as from additional interventions aimed at preventing the vertical (mother-to-child) spread of the virus | 50% | 70% | 90% |
| | Children's vaccination coverage against hepatitis B (third dose) | 90% | 90% | 90% |
| | The quantity of syringes and needles given to each drug injector | 200 | 200 | 300 |
| | The percentage of blood units checked for bloodborne infections is known as blood safety. | 95% | 100% | 100% |
| | Safe injections: percentage of safe injections used in healthcare | 95% | 100% | 100% |
| Milestones | Planning: the count of nations having budgeted plans to eradicate hepatitis | TBD | 30 | 50 |
| | Surveillance - number of nations that yearly report on burden and cascade | 130 | 150 | 170 |
| | Hepatitis C virus drug access - % average price drop (to 2025 equivalent generic pricing) | 20% | 50% | 60% |
| | Hepatitis B virus drug access - % average price drop (to be in line with HIV medication costs by 2025) | 20% | 50% | 60% |
| | Elimination of vertical (mother-to-child) transmission - number of nations whose efforts to end the vertical spread of syphilis, hepatitis B, or HIV have been verified | 15 | 50 | 100 |
| | Elimination - number of nations where the eradication of hepatitis C and/or hepatitis B has been validated | 0 | 5 | 20 |
| | Integration - percentage of HIV-positive individuals who were tested for/cured of hepatitis C | TBD | 60%/50% | 90%/80% |

in order to eradicate the illness as a danger to public health by 2030 (Table 1).^{3,28,29} With a high coverage of preventative treatments, this strategy offers countries a framework to monitor their success in lowering hepatitis B and C infections and related mortality. Infant hepatitis B immunizations, safe blood and injection practices, harm reduction, HBV/HCV testing and treatment, etc. are some of these approaches.¹⁴

The majority of African nations still have draft national hepatitis strategies, despite this strategic objective. Less than eight nations in the region provide subsidized hepatitis testing and treatment, leaving large gaps in the market. Securing sufficient finance, political support, the ability of the health system, community involvement, and the preservation of the human rights of hepatitis C patients are among the difficulties.^{14,27,30}

A notable example of how a nation might tackle a significant public health burden is Egypt's program, which started in 2014 and accelerated in 2018, with the goal of eradicating hepatitis C by 2023. Key elements included administering direct-acting antivirals (DAAs), which can cure more than 95% of instances of hepatitis C, to everyone diagnosed with the condition nationally and evaluating them for noncommunicable diseases (NCDs) like diabetes and hypertension. Public health institutions offered free care, which was made possible by creative financing methods like social solidarity funds and health insurance, as well as locally produced generic DAAs and negotiated price reductions,^{15,25} to enhance blood safety, infection control, and harm reduction procedures in order to stop the spread of new infections. The program also raised awareness about hepatitis C transmission and prevention among the general public and healthcare providers. Additionally, it promoted the hepatitis B vaccination, which can prevent hepatitis D co-infection. Finally, it used a comprehensive surveillance system, which included sentinel sites, regular surveys, and viral load testing, to monitor and assess the program's effectiveness. The World Health Organization (WHO) and other partners worked with the initiative to verify its successes and disseminate the lessons it had learnt.^{19,31–34}

The program produced remarkable and unheard-of results. Over 60 million people had been examined and over 4 million had been treated by the program by 2022. In Egypt, the frequency of new infections fell from 300 per 100,000 in 2014 to 9 per 100,000 in 2022, and the prevalence of hepatitis C fell from 10% in 2014 to 0.38% in 2022.^{18,24} Egypt is the first nation to reach the “gold tier” designation on the WHO's route to hepatitis C eradication, meaning it has met the coverage goals for the program, which will allow it to reach the 2030 full elimination targets for reduced incidence and mortality.²⁸

Egypt's Hepatitis C Elimination Program: Lessons to Be Learned and Advice for Other African Nations

An estimated 1.4 million fatalities, 3.5 million new infections, and 62 billion USD in economic damages might be avoided if hepatitis C is eradicated in Africa by 2030.^{3,4,35–37} As a result, we urge all parties involved to step up their financial support, political dedication, and teamwork in order to eradicate hepatitis C in Africa and enable millions of people to live healthy, fulfilling lives.

Other African nations with limited resources, infrastructure, and knowledge that confront a high incidence of Hepatitis B or C infections should take inspiration from Egypt's methodology for eradicating the disease.^{35,38} However, each nation must modify the model and take into account the WHO Strategic plan in light of its unique circumstances, taking into account the capacity of the health system, the political climate, cultural norms, and the epidemiology, transmission, and risk factors of hepatitis C.

Egypt's incredible achievement was made possible by its innovative finance and collaborations, political dedication and leadership, and community awareness and mobilization. These elements made it possible for Egypt to carry out an extensive and ambitious program that impacted millions of individuals nationwide and encompassed hepatitis C screening, diagnosis, treatment, prevention, and surveillance.^{16,19,37,39,40}

We advise African governments, international organizations, and other stakeholders to take the following steps to expedite hepatitis C elimination efforts in Africa, based on Egypt's success story:

- o *Perform a gap analysis and scenario analysis* to determine the extent and features of the hepatitis C outbreak as well as the advantages and disadvantages of the current approach. This could entail mapping stakeholders and resources, evaluating policies and guidelines, and conducting seroprevalence surveys.^{16,39}
- o *Create and carry out national hepatitis C operational and strategic plans* that are in line with the priorities and context of the nation, based on the WHO global health sector strategy and the regional framework for action.^{3,24}
- o *Create a governance framework and a national coordinating mechanism* to supervise and monitor the program and guarantee accountability and openness. Establishing a national committee or technical working group including members from the government, academia, civil society, and development partners is one way to do this.

- o To finance and carry out hepatitis C elimination programs, as well as to take advantage of already-existing platforms and initiatives, mobilize both internal and external resources and collaborations. In order to do this, one could propose raising the budget, apply for grants from the Global Fund and other sources, bargain with drug companies for voluntary licenses and price reductions, and work with other health initiatives related to HIV, TB, and noncommunicable diseases.^{18,29,38,41}
- o Launch phased and prioritized hepatitis C elimination programs, focusing first on the most vulnerable and impacted populations and regions before progressively and methodically scaling them up.^{11,13,42,43} In addition to using a patient-centered and human rights-based approach, the programs should address the following components: screening, diagnosis, treatment, prevention, and surveillance.
- o Boost the capabilities of health systems and the medical staff to provide safe and effective hepatitis C services, as well as to guarantee the accessibility and availability of medications and tests.^{24,28,44} This could involve developing blood safety and infection control procedures, strengthening supply chain and logistics management, and educating and inspiring healthcare professionals.
- o Apply the WHO validation criteria and tools, as well as a reliable and standardized data collecting and reporting system, to track and assess the program's effectiveness.^{18,28} In order to make improvements, the program should also carry out routine reviews and evaluations, distribute the results, and apply the lessons discovered.
- o Increase community involvement and public awareness in order to combat stigma and prejudice against those who are hepatitis C positive or at risk, as well as to boost demand for and uptake of hepatitis C services. This can entail running social media campaigns to encourage behavior changes, disseminating accurate and trustworthy information, and incorporating celebrities, religious institutions, and civil society organizations into the initiative.^{45,46}

Enhancing access to diagnosis and treatment through the decentralization and simplification of the service delivery model, connecting hepatitis C services with other health services, and utilizing point-of-care and self-testing technologies are additional tactics and interventions that could aid in the eradication of hepatitis C in Africa.^{18,24} Bolstering health systems through increasing the ability and drive of healthcare professionals, guaranteeing the standard and security of medical care, and streamlining the distribution and handling of pharmaceuticals and diagnostics.^{42,47} Raising public awareness through tackling stigma and prejudice against those who have hepatitis B and C or are at risk of getting it, implementing social and behavior change communication initiatives, and supplying accurate and trustworthy information.^{2,45,47,48}

Conclusion

Millions of fatalities can be avoided and significant improvements in public health can be achieved if HBV and HCV infections are eradicated by 2030. Much of what's required to accomplish these aims already exists. Chronic HCV must be eradicated immediately and completely. Ingenious barrier-breaking measures by African health systems are required to accomplish this goal. Success requires modifying WHO's objectives and approach as well as providing resources, awareness, training, and training. Egypt's national hepatitis C elimination campaign is an example of a successful approach to this task, despite the difficulties involved. To lower morbidity and death, it is imperative to take lessons from Egypt's historic achievement. Overall, countries with national programs that included extensive HCV screening and treatment initiatives have had exceptional success; on the other hand, countries without such programs continue to have high HCV burdens. For the millions of people who deserve a healthier, more respectable life, hepatitis C elimination must be a reality, requiring cooperation from all parties involved.

Acknowledgment

This paper has been uploaded to preprint.org as a preprint: <https://wpwww.preprints.org/manuscript/202403.0935/v1>

Disclosure

The authors report no conflicts of interest in this work.

References

1. World Health Organisation. Hepatitis C. *J*. 2024. 16.
2. Taha G, Ezra L, Abu-Freha N. Hepatitis C elimination: opportunities and challenges in 2023. *Viruses*. 2023;15(7, Art. no. 7):1413. doi:10.3390/v15071413
3. Sonderup MW, Afihene M, Ally R, et al. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. *Lancet Gastroenterol Hepatol*. 2017;2(12):910–919. doi:10.1016/S2468-1253(17)30249-2
4. Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. *Pan Afr Med J*. 2013;14(44, Art. no. 44). doi:10.11604/pamj.2013.14.44.2199
5. de Oliveira Andrade LJ, D'Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. *J Glob Infect Dis*. 2009;1(1):33–37. doi:10.4103/0974-777X.52979
6. “Pathogenesis of hepatitis C virus-related hepatocellular carcinoma: evidence from recent studies - Maruyama - Journal of Public Health and Emergency”: Jan. 16, 2024. [Online]. Available: <https://jphe.amegroups.org/article/view/7483/html>.
7. Hepatitis C virus and hepatocellular carcinoma: a narrative review - PMC. *J*. 2024;16. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863002/>.
8. Systematic review of prevalence and risk factors of transfusion transmissible infections among blood donors, and blood safety improvements in Southern Africa | request PDF. *ResearchGate*. 2023. doi:10.1111/tme.12988
9. Hasan Mohamed El-Sagheer S, Castro O, Giday SA, “HCV in sickle cell disease”. Accessed: Jan. 16, 2024. [Online]. Available: https://www.researchgate.net/publication/9065255_HCV_in_sickle_cell_disease.
10. “Trends of the global hepatitis C disease burden: Strategies to achieve elimination”. Accessed: Jan. 16, 2024. [Online]. Available: <https://www.jpmph.org/journal/view.php?number=2154>.
11. Seu R, et al. Challenges and best practices for hepatitis c care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya. *Glob Public Health*. 2022;17(12):3627. doi:10.1080/17441692.2022.2110919
12. Mohd Suan MA, Said SM, Lim PY, Azman AZF, Abu Hassan MR. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: a case–control study. *PLoS One*. 2019;14(10):e0224459. doi:10.1371/journal.pone.0224459
13. Nurudtinova D, Abdallah AB, Bradford S, O’Leary CC, Cottler LB, “Risk factors associated with hepatitis C among female substance users enrolled in community-based HIV prevention studies - PMC”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095996/>.
14. WHO Africa region, “Hepatitis Scorecard for the WHO Africa region implementing the hepatitis elimination strategy”, WHO | Regional Office for Africa. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.afro.who.int/publications/hepatitis-scorecard-who-africa-region-implementing-hepatitis-elimination-strategy>.
15. WHO Africa, “New WHO scorecard shows poor progress of the viral hepatitis response in the African region”, WHO | Regional Office for Africa. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.afro.who.int/news/new-who-scorecard-shows-poor-progress-viral-hepatitis-response-african-region>.
16. Hopkins University J, Baltimore MDUSA, “Progress towards elimination goals for viral hepatitis - PMC”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376316/>.
17. Popping S, Bade D, Boucher C, et al. The global campaign to eliminate HBV and HCV infection: international viral hepatitis elimination meeting and core indicators for development towards the 2030 elimination goals. *J Virus Erad*. 2019;5(1):60. doi:10.1016/S2055-6640(20)30281-8
18. WHO, “Access to treatment and care for all: the path to eliminate hepatitis C in Egypt”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.who.int/news-room/feature-stories/detail/access-to-treatment-and-care-for-all-the-path-to-eliminate-hepatitis-c-in-egypt>.
19. Hassanin A, “Egypt’s ambitious strategy to eliminate hepatitis C Virus: A case study - PMC”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087425/>.
20. Ammal M. Metwally, “accelerating hepatitis C virus elimination in Egypt by 2030: a national survey of communication for behavioral development as a modelling study - PMC”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901784/>.
21. Ismail KH, Iii DEL-P. The need to re-invigorate initiatives against Hepatitis C in Egypt. *Popul Med*. 2023;5(February):1–2. doi:10.18332/popmed/160080
22. Hassany M, Abdel-Razek W, AbdAllah M, “WHO awards Egypt with gold tier status on the path to eliminate hepatitis C - the lancet gastroenterology & hepatology”. Accessed: Jan. 17, 2024. [Online]. Available: [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(23\)00364-3/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00364-3/fulltext).
23. Azevedo MJ, “The state of health system(s) in Africa: challenges and opportunities - PMC”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123888/>.
24. Schröder SE, Pedrana A, Scott N, et al. Innovative strategies for the elimination of viral hepatitis at a national level: a country case series. *Liver Int*. 2019;39(10):1818–1836. doi:10.1111/liv.14222
25. Daw MA, 2024,*Abdallah El-Bouzedi, 2 Mohamed O. Ahmed, 3 Aghnyia A. Dau, 4 and Mohamed M. Agnan 5, “Hepatitis C Virus in North Africa: an Emerging Threat - PMC”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004010/>.
26. IHME. Global Burden of Disease Study. 2019; Available from: <https://ourworldindata.org/grapher/hepatitis-c-number-of-deaths?region=Africa>.
27. Raad I, Chafitari A-M, Torres HA, et al. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. *World J Hepatol*. 2018;10:549–557. doi:10.4254/wjh.v10.i9.549
28. WHO, “WHO releases first-ever global guidance for country validation of viral hepatitis B and C elimination”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.who.int/news/item/25-06-2021-who-releases-first-ever-global-guidance-for-country-validation-of-viral-hepatitis-b-and-c-elimination>.
29. WHO, “Manual for the development and assessment of national viral hepatitis plans”. Accessed: Jan. 17, 2024. [Online]. Available: <https://www.who.int/publications/i/item/9789241509350>.
30. The Opportunity to Eliminate Hepatitis C through Alternative Financing Mechanisms. *J*. 2024;17. [Online]. Available: https://endhep2030.org/wp-content/uploads/2022/06/Policy-Brief_HCV.pdf.

31. Klein F. 100 million seha: Egypt's war against hepatitis C. *PharmaBoard*. 2024;17. [Online]. Available <https://pharmaboardroom.com/articles/100-million-seha-egypts-war-against-hepatitis-c/>.
32. WHO, "WHO commends Egypt for its progress on the path to eliminate hepatitis C". Accessed: Jan. 17, 2024. [Online]. Available: https://assumption-prod.modolabs.net/parents_families/au_news/detail?feed=wr_crisis_response_who_news&id=7a0bad49-4b30-55eb-be91-6f9af408d33c&_kgoui_bookmark=f0f0ee60-484b-5273-9b0d-3c0e7b37a3fa. Accessed May 28 2024.
33. WHO, "Egypt becomes the first country to achieve WHO validation on the path to elimination of hepatitis C", World Health Organization - Regional Office for the Eastern Mediterranean. Accessed: Jan. 17, 2024. [Online]. Available: <http://www.emro.who.int/media/news/egypt-becomes-the-first-country-to-achieve-who-validation-on-the-path-to-elimination-of-hepatitis-c.html>.
34. Jordano J, Curkovic N, Aggarwal S, Hutcheson K, "(PDF) hepatitis C treatment for patients without insurance in a student-run free clinic: analysis of demographics, cost, and outcomes". Accessed: Jan. 17, 2024. [Online]. Available: https://www.researchgate.net/publication/374954336_Hepatitis_C_Treatment_for_Patients_Without_Insurance_in_a_Student-Run_Free_Clinic_Analysis_of_Demographics_Cost_and_Outcomes. Accessed May 28 2024
35. Elbahrawy A, Ibrahim MK, Eliwa A, Alborai M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. *Microbiol Immunol*. 2021;65(9):352–372. doi:10.1111/1348-0421.12916
36. Deress T, Million Y, Belachew T, Jemal M, Girma M. Seroprevalence of hepatitis c viral infection in Ethiopia: a systematic review and meta-analysis. *Sci World J*. 2021;2021:e8873389. doi:10.1155/2021/8873389
37. "prevalence of hepatitis B and hepatitis C in migrants from sub-saharan Africa before onward dispersal toward Europe | Journal of Immigrant and Minority Health". Accessed: Jan. 17, 2024. [Online]. Available: <https://link.springer.com/article/10.1007/s10903-022-01448-z>.
38. WHO, "Prevention and control of viral hepatitis infection: Framework for global action". Accessed: Jan. 17, 2024. [Online]. Available: <https://www.who.int/publications-detail-redirect/prevention-and-control-of-viral-hepatitis-infection-framework-for-global-action>.
39. "Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges | future virology". Accessed: Jan. 17, 2024. [Online]. Available: <https://www.futuremedicine.com/doi/10.2217/fvl.13.11>.
40. "The art and science of eliminating hepatitis: Egypt's experience". Accessed: Jan. 17, 2024. [Online]. Available: https://www3.weforum.org/docs/WEF_The_Art_and_Science_of_Eliminating_Hepatitis_Egypt's_Experience_2022.pdf.
41. Margaret H, Sophia E S, Pedrana A, "The elimination of hepatitis c as a public health threat - PMC". Accessed: Jan. 17, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117951/>.
42. Petruzzello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. *World J Gastroenterol*. 2016;22(34):7824–7840. doi:10.3748/wjg.v22.i34.7824
43. ministry of health Malaysia, "National Institutes of Health - NIH official portal". Accessed: Jan. 17, 2024. [Online]. Available: <https://nih.gov.my/>.
44. Cox AL, El-Sayed MH, Kao J-H, et al., "Progress towards elimination goals for viral hepatitis | nature reviews gastroenterology & hepatology". Accessed: Jan. 17, 2024. [Online]. Available: <https://www.nature.com/articles/s41575-020-0332-6>.
45. Ha S, Timmerman K. Awareness and knowledge of hepatitis C among health care providers and the public: a scoping review. *Can Commun Dis Rep*. 2018;44(7–8):157–165. doi:10.14745/ccdr.v44i78a02
46. Li T, Wang R, Zhao Y, Su S, Zeng H. Public awareness and influencing factors regarding hepatitis B and hepatitis C in Chongqing municipality and Chengdu City, China: a cross-sectional study with community residents. *BMJ Open*. 2021;11(8):e045630. doi:10.1136/bmjopen-2020-045630
47. WHO, "Consolidated strategic information guidelines for viral hepatitis planning and tracking progress towards elimination: guidelines". Accessed: Jan. 17, 2024. [Online]. Available: <https://www.who.int/publications-detail-redirect/9789241515191>.
48. I. of M. (US) C. on the P. and C. of V. H. Infection, H. M. Colvin, and A. E. Mitchell, "knowledge and awareness about chronic hepatitis b and hepatitis C. *Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C*. National Academies Press (US,2010. [Online]. Available. <https://www.ncbi.nlm.nih.gov/books/NBK220038/>. Accessed May 28 2024.

Hepatic Medicine: Evidence and Research

Dovepress

Publish your work in this journal

Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access journal covering all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease; Investigation and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease. Issues of patient safety and quality of care will also be considered. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/hepatic-medicine-evidence-and-research-journal>